Journal article

Citalopram and Cannabidiol In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People

Lyndsey L Anderson, Peter T Doohan, Lachlan Oldfield, Richard C Kevin, Jonathon C Arnold, Maximus Berger, G Paul Amminger, Iain S McGregor

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

Abstract

BACKGROUND: Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits anxiolytic properties in preclinical and human studies and is of interest as a novel intervention for treating anxiety disorders. Existing first-line pharmacotherapies for these disorders include selective serotonin reuptake inhibitor and other antidepressants. Cannabidiol has well-described inhibitory action on cytochrome P450 (CYP450) drug-metabolizing enzymes and significant drug-drug interactions (DDIs) between CBD and various anticonvulsant medications (eg, clobazam) have been described in the treatment of epilepsy. Here, we examined the likelihood of DDIs when CBD is added to medications prescribed..

View full abstract

Grants

Funding Acknowledgements

This study was supported by the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded center for medicinal cannabis research at the University of Sydney. The authors thank Barry and Joy Lambert for their continued support of the Lambert Initiative for Cannabinoid Therapeutics.